Real-world Comparative Effectiveness of Apixaban Versus Vitamin K Antagonist
Status:
Completed
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
To obtain a better understanding on the comparative effectiveness of apixaban versus VKA
(Vitamin K antagonist) for stroke prevention in patients with NVAF (Non-valvular atrial
fibrillation) in a real-life setting.